Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Antineoplastic Agents

All Drugs and Chemicals

Sotorasib

Immune Checkpoint Inhibitors

Antineoplastic Agents, Immunological

Sotorasib : 120 mg, once a day, per os, until progression, unacceptable toxicity, death or lost to follow-up

Daily sotorasib treatment until progression, unacceptable toxicity, death, or lost to follow-up

Sotorasib 120Mg Tab

Thibault RAOULT, MSc

Aurélie SWALDUZ, MD

Pascale TOMASINI, MD

Jacques CADRANEL, MD

Mihaela ALDEA, MD

This study aims to provide a comprehensive understanding of sotorasib's mechanisms of action and resistance in NSCLC patients.

Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

An Interventional and Translational Study Investigating Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

To evaluate tumor response at 4 months and decipher relevant biomarkers associated with primary (progression within the first 4 months) and acquired resistance to sotorasib (progression after 4 months).

Gustave Roussy, Cancer Campus, Grand Paris

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C	NCT05631249	KRAS P.G12C Non Small Cell ...	Sotorasib 120Mg...	18 Years -	Gustave Roussy, Cancer Campus, Grand Paris
Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C	NCT05631249	KRAS P.G12C Non Small Cell ...	Sotorasib 120Mg...	18 Years -	Gustave Roussy, Cancer Campus, Grand Paris

Spots Global Cancer Trial Database for sotorasib 120mg tab